Literature DB >> 18157514

Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.

Michael J Mauro1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18157514     DOI： 10.1007/s11864-007-0036-y

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


× No keyword cloud information.
  20 in total

Review 1.  The development of imatinib as a therapeutic agent for chronic myeloid leukemia.

Authors:  Michael Deininger; Elisabeth Buchdunger; Brian J Druker
Journal:  Blood       Date:  2004-12-23       Impact factor: 22.113

2.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

3.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

Authors:  T Schindler; W Bornmann; P Pellicena; W T Miller; B Clarkson; J Kuriyan
Journal:  Science       Date:  2000-09-15       Impact factor: 47.728

4.  High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

Authors:  Stephanie G Willis; Thoralf Lange; Shadmehr Demehri; Sandra Otto; Lucy Crossman; Dietger Niederwieser; Eric P Stoffregen; Shannon McWeeney; Ines Kovacs; Byung Park; Brian J Druker; Michael W Deininger
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

5.  Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

Authors:  Hagop Kantarjian; Ricardo Pasquini; Nelson Hamerschlak; Philippe Rousselot; Jerzy Holowiecki; Saengsuree Jootar; Tadeusz Robak; Nina Khoroshko; Tamas Masszi; Aleksander Skotnicki; Andrzej Hellmann; Andrey Zaritsky; Anatoly Golenkov; Jerald Radich; Timothy Hughes; Athena Countouriotis; Neil Shah
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

6.  Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.

Authors:  Martine Gardembas; Philippe Rousselot; Michel Tulliez; Magda Vigier; Agnes Buzyn; Francoise Rigal-Huguet; Laurence Legros; Mauricette Michallet; Christian Berthou; Nathalie Cheron; Frederic Maloisel; Francois-Xavier Mahon; Thierry Facon; Patrice Berthaud; Joelle Guilhot; Francois Guilhot
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

7.  Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

Authors:  Bin Peng; Michael Hayes; Debra Resta; Amy Racine-Poon; Brian J Druker; Moshe Talpaz; Charles L Sawyers; Marianne Rosamilia; John Ford; Peter Lloyd; Renaud Capdeville
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

Review 8.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

9.  Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

Authors:  A Hochhaus; S Kreil; A S Corbin; P La Rosée; M C Müller; T Lahaye; B Hanfstein; C Schoch; N C P Cross; U Berger; H Gschaidmeier; B J Druker; R Hehlmann
Journal:  Leukemia       Date:  2002-11       Impact factor: 11.528

10.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

Authors:  Nicholas J Donato; Ji Yuan Wu; Jonathan Stapley; Gary Gallick; Hui Lin; Ralph Arlinghaus; Moshe Talpaz
Journal:  Blood       Date:  2003-01-15       Impact factor: 22.113
View more
  1 in total

Review 1.  Chronic myeloid leukemia: mechanisms of resistance and treatment.

Authors:  Elias Jabbour; Sameer A Parikh; Hagop Kantarjian; Jorge Cortes
Journal:  Hematol Oncol Clin North Am       Date:  2011-10-19       Impact factor: 3.722
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.